Literature DB >> 20061432

Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.

Zeina A Habib1, Suzanne L Havstad, Karen Wells, George Divine, Manel Pladevall, L Keoki Williams.   

Abstract

CONTEXT: Thiazolidinedione (TZD) use has recently been associated with an increased risk of fractures.
OBJECTIVE: The aim of this study was to determine the time-dependent relationship between TZD use and fracture risk.
DESIGN: We conducted a retrospective cohort study in a large health system in southeast Michigan. PATIENTS: PATIENTS who received care from the health system were included if they were at least 18 yr of age, had a diagnosis of diabetes, and had at least one prescription for an oral diabetes medication. These criteria identified 19,070 individuals (9,620 women and 9,450 men). INTERVENTION: This study compared patients treated with TZDs to patients without TZD treatment. Cox proportional hazard models were used to assess the relationship between exposure and outcomes. MAIN OUTCOME MEASURES: The primary outcome was the time to fracture. Secondary analyses examined the risk of fractures in subgroups defined by sex and age.
RESULTS: TZD use was associated with an increased risk of fracture in the cohort overall [adjusted hazard ratio (aHR), 1.35; 95% confidence interval (CI), 1.05-1.71] and in women (aHR, 1.57; 95% CI, 1.16-2.14), but not in men (aHR, 1.05; 95% CI, 0.70-1.58). Women more than 65 yr of age appeared to be at greatest risk for fracture (aHR, 1.72; 95% CI, 1.17-2.52). Among women, the increased fracture risk was not apparent until after 1 yr of TZD treatment.
CONCLUSIONS: TZD use was associated with an increased risk for fractures in women, particularly at ages above 65 yr. Clinicians should be aware of this association when considering TZD therapy so as to appropriately manage and counsel their patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061432      PMCID: PMC2840855          DOI: 10.1210/jc.2009-1385

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  45 in total

1.  Neuropathy-induced osteopenia in rats is not due to a reduction in weight born on the affected limb.

Authors:  Garth T Whiteside; Jamie M Boulet; Rani Sellers; Tracie E Bunton; Katharine Walker
Journal:  Bone       Date:  2005-10-03       Impact factor: 4.398

2.  Higher incidence of falls in long-term stroke survivors than in population controls: depressive symptoms predict falls after stroke.

Authors:  Lone Jørgensen; Torgeir Engstad; Bjarne K Jacobsen
Journal:  Stroke       Date:  2002-02       Impact factor: 7.914

3.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

4.  Thiazolidinediones and fractures in men and women.

Authors:  Colin R Dormuth; Greg Carney; Bruce Carleton; Ken Bassett; James M Wright
Journal:  Arch Intern Med       Date:  2009-08-10

5.  Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis.

Authors:  M Alexandra Sorocéanu; Dengshun Miao; Xiu-Ying Bai; Hanyi Su; David Goltzman; Andrew C Karaplis
Journal:  J Endocrinol       Date:  2004-10       Impact factor: 4.286

6.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

7.  A computer assisted photogrammetric analysis of soft tissue changes after orthodontic treatment. Part I: Methodology and reliability.

Authors:  S E Bishara; D M Cummins; G J Jorgensen; J R Jakobsen
Journal:  Am J Orthod Dentofacial Orthop       Date:  1995-06       Impact factor: 2.650

8.  Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).

Authors:  V Sottile; K Seuwen; M Kneissel
Journal:  Calcif Tissue Int       Date:  2004-07-13       Impact factor: 4.333

9.  Diabetes, TZDs, and Bone: A Review of the Clinical Evidence.

Authors:  Ann V Schwartz
Journal:  PPAR Res       Date:  2006       Impact factor: 4.964

10.  The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.

Authors:  Ian J Douglas; Stephen J Evans; Stuart Pocock; Liam Smeeth
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more
  58 in total

Review 1.  Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option?

Authors:  Marcus D Säemann; Michael Krebs
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

2.  CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation.

Authors:  Cody C Wyles; Christopher R Paradise; Matthew T Houdek; Susan L Slager; Andre Terzic; Atta Behfar; Andre J van Wijnen; Rafael J Sierra
Journal:  Clin Orthop Relat Res       Date:  2019-08       Impact factor: 4.176

Review 3.  Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.

Authors:  James H O'Keefe; Mohammad Abuannadi; Carl J Lavie; David S H Bell
Journal:  Mayo Clin Proc       Date:  2011-01-26       Impact factor: 7.616

Review 4.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

5.  Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.

Authors:  Luigi Brunetti; Julie Kalabalik
Journal:  P T       Date:  2012-12

6.  Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.

Authors:  Domenico Motola; Carlo Piccinni; Chiara Biagi; Emanuel Raschi; Anna Marra; Giulio Marchesini; Elisabetta Poluzzi
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

Review 7.  Bone metabolism in obesity and weight loss.

Authors:  Sue A Shapses; Deeptha Sukumar
Journal:  Annu Rev Nutr       Date:  2012-08-21       Impact factor: 11.848

Review 8.  Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.

Authors:  Valerio Nobili; Arun J Sanyal
Journal:  J Gastroenterol       Date:  2011-10-08       Impact factor: 7.527

9.  Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction.

Authors:  Mostafa El-Refai; Edward L Peterson; Karen Wells; Tanmay Swadia; Hani N Sabbah; John A Spertus; L Keoki Williams; David E Lanfear
Journal:  J Card Fail       Date:  2013-02       Impact factor: 5.712

10.  Rosiglitazone disrupts endosteal bone formation during distraction osteogenesis by local adipocytic infiltration.

Authors:  Lichu Liu; James Aronson; Beata Lecka-Czernik
Journal:  Bone       Date:  2012-10-13       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.